MiMedx
-
Biologics
MiMedx Agrees To Lawsuit Settlement With Halo Wound Solutions
MARIETTA, Ga., Nov. 1, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic…
Read More » -
Biologics
MiMedx Notified By FDA That It Can Proceed With Phase 2B Investigational New Drug Clinical Trial For Osteoarthritis Of The Knee
MARIETTA, Ga., Oct. 17, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic…
Read More » -
Biologics
MiMedx Warns Of Fake Emails
MARIETTA, Ga., Oct. 17, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic…
Read More » -
Financial
MiMedx Announces Third Quarter Revenues Of $84.6 Million Exceeds Guidance By More Than 5 Percent
MARIETTA, Ga., Oct. 10, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics…
Read More » -
Financial
MiMedx Board of Directors Authorizes $10 Million Increase to the Company’s Share Repurchase Program
MARIETTA, Ga., Oct. 9, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics…
Read More » -
Biologics
Dr. Gloria Matthews Joins MiMedx As Its Senior Vice President Of Research And Development
MARIETTA, Ga., Oct. 3, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic…
Read More » -
Biologics
Court Sets the Trial Date for MiMedx Patent Infringement Lawsuit Against MTF, Medline and Liventa
MARIETTA, Ga., Oct. 2, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics…
Read More » -
Biologics
MiMedx To Host Shareholder Call On September 21, 2017 To Update Progress On Various Strategic Initiatives And Respond To Topics Requested By Shareholders
MARIETTA, Ga., Sept. 19, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic…
Read More » -
Biologics
MiMedx Files With The FDA To Initiate The Company’s Investigational New Drug Phase 2 Clinical Trial For Osteoarthritis Of The Knee
MARIETTA, Ga., Sept. 19, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics…
Read More » -
Financial
MiMedx Reiterates Its Third Quarter Revenue Expectation To Exceed $80 Million Despite Hurricane Irma
MARIETTA, Ga., Sept. 13, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics…
Read More » -
Biologics
MiMedx Recognized as Number 5 on Fortune Magazine’s List of the 100 Fastest Growing Public Companies
MARIETTA, Ga., Sept. 12, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics…
Read More » -
Biologics
MiMedx Reports MultiCenter randomized Controlled VLU Clinical Study Accepted for Publication in The International Wound Journal
MARIETTA, Ga., Aug. 31, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics…
Read More » -
Biologics
MiMedx Signs Definitive Agreement to Divest Stability Biologics Subsidiary as Company’s Strategic Focus on Biopharma
MARIETTA, Ga., Aug. 18, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics…
Read More » -
Biologics
MiMedx Hits Milestone of One Million Allografts Distributed
MARIETTA, Ga., Aug. 9, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and…
Read More » -
Extremities
MiMedx Initiates Phase 3 Plantar Fasciitis Clinical Trial
MARIETTA, Ga., Aug. 2, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics…
Read More »